Arrowhead Pharmaceuticals Inc (ARWR)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-296,814	-205,275	-181,107	-150,207	-154,516	-176,063	-153,926	-111,804	-182,988	-140,848	-125,907	-109,594	-102,612	-84,553	-24,415	9,532	53,265	67,975	45,509	9,567
Total assets	US$ in thousands	626,286	765,552	795,856	891,308	891,489	691,939	751,782	703,575	638,539	710,148	734,927	756,795	499,251	522,504	555,728	561,076	587,602	349,845	336,828	333,940
ROA		-47.39%	-26.81%	-22.76%	-16.85%	-17.33%	-25.44%	-20.47%	-15.89%	-28.66%	-19.83%	-17.13%	-14.48%	-20.55%	-16.18%	-4.39%	1.70%	9.06%	19.43%	13.51%	2.86%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $-296,814K ÷ $626,286K
= -47.39%

The return on assets (ROA) for Arrowhead Pharmaceuticals Inc. has shown variability over the past eight quarters. The ROA ranged from a low of -47.39% in Q1 2024 to a high of -15.89% in Q2 2022. During this period, the company experienced fluctuations in its ability to generate profits from its assets, with negative ROA values indicating that the company's assets were not generating sufficient earnings to cover its expenses. The declining trend in ROA from Q2 2022 to Q1 2024 may suggest challenges in efficiently utilizing its assets to generate profits. It is important for the company to closely monitor and improve its asset management strategies to enhance its profitability and financial performance in the future.